President Trump's Pledge to Lower Medicaid Drug Prices Faces Implementation Challenges and Lack of Transparency
A year after President Trump pledged to significantly lower Medicaid drug prices through 'most favored nation' deals with pharmaceutical companies, the initiative has been plagued by uncertainties, delays, and a lack of transparency. In September 2025, President Trump announced that Pfizer would offer all its prescription medications to Medicaid at 'most favored nation prices,' expecting other drug companies to follow suit. While the White House claimed 26 companies signed agreements, these agreements have not been made public. The program, known as the Generous pilot, relies on voluntary participation from both drug companies and individual states. However, companies are not confirming that all their drugs will be discounted, with some indicating only 'selected' or 'certain' products will be included. Additionally, states must opt-in and agree to standardized coverage criteria, which could force them to offer unfettered access to drugs, potentially increasing overall spending despite lower per-drug prices...
